A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes

[1]  Annette S. Kim,et al.  miR-378-3p Knockdown Recapitulates Many of the Features of Myelodysplastic Syndromes. , 2021, The American journal of pathology.

[2]  S. Lim,et al.  TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy , 2021, Current issues in molecular biology.

[3]  Ming Yao,et al.  LncRNA CD27-AS1 promotes acute myeloid leukemia progression through the miR-224-5p/PBX3 signaling circuit , 2021, Cell Death & Disease.

[4]  A. Alfonso-Pierola,et al.  Current Therapy of the Patients with MDS: Walking towards Personalized Therapy , 2021, Journal of clinical medicine.

[5]  Qinghua Li,et al.  Circular RNA circ_0005774 contributes to proliferation and suppresses apoptosis of acute myeloid leukemia cells via circ_0005774/miR-192-5p/ULK1 ceRNA pathway. , 2021, Biochemical and biophysical research communications.

[6]  Yao Yao,et al.  Emerging Role of MiR-192-5p in Human Diseases , 2021, Frontiers in Pharmacology.

[7]  Heather J. Lee,et al.  Unravelling the Epigenome of Myelodysplastic Syndrome: Diagnosis, Prognosis, and Response to Therapy , 2020, Cancers.

[8]  B. Seliger,et al.  Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins , 2020, International journal of molecular sciences.

[9]  Dapeng Sun,et al.  Identifying of miR-98-5p/IGF1 axis contributes breast cancer progression using comprehensive bioinformatic analyses methods and experiments validation. , 2020, Life sciences.

[10]  A. Goldberg,et al.  Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. , 2020, Blood advances.

[11]  M. Caligiuri,et al.  Combined loss of function of two different loci of miR-15/16 drives the pathogenesis of acute myeloid leukemia , 2020, Proceedings of the National Academy of Sciences.

[12]  Duncan Ayers,et al.  Overview of current microRNA biomarker signatures as potential diagnostic tools for leukaemic conditions , 2020, Non-coding RNA research.

[13]  C. Croce,et al.  MicroRNA dysregulation and multi-targeted therapy for cancer treatment. , 2020, Advances in biological regulation.

[14]  Fei Wang,et al.  miRTarBase 2020: updates to the experimentally validated microRNA–target interaction database , 2019, Nucleic Acids Res..

[15]  Xiaowei Wang,et al.  miRDB: an online database for prediction of functional microRNA targets , 2019, Nucleic Acids Res..

[16]  H. Chung,et al.  miR-222 represses expression of zipcode binding protein-1 and phospholipase C-γ1 in intestinal epithelial cells. , 2019, American journal of physiology. Cell physiology.

[17]  M. Gobbi,et al.  Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes , 2019, Leukemia.

[18]  C. Craddock,et al.  Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  B. Feinberg,et al.  Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes , 2019, Leukemia & lymphoma.

[20]  P. Hrelia,et al.  Meripilus giganteus ethanolic extract exhibits pro-apoptotic and anti-proliferative effects in leukemic cell lines , 2018, BMC Complementary and Alternative Medicine.

[21]  J. McCubrey,et al.  Nuclear phospholipase C isoenzyme imbalance leads to pathologies in brain, hematologic, neuromuscular, and fertility disorders[S] , 2018, Journal of Lipid Research.

[22]  Yu-Chiao Chiu,et al.  The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome , 2018, Blood Cancer Journal.

[23]  Yu-Chiao Chiu,et al.  The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome , 2018, Blood Cancer Journal.

[24]  F. Gao,et al.  Downregulation of microRNA-21 expression inhibits proliferation, and induces G1 arrest and apoptosis via the PTEN/AKT pathway in SKM-1 cells , 2018, Molecular medicine reports.

[25]  Jun Lu,et al.  MicroRNA-192 regulates cell proliferation and cell cycle transition in acute myeloid leukemia via interaction with CCNT2 , 2017, International Journal of Hematology.

[26]  Dongshan Zhang,et al.  p53 activates miR-192-5p to mediate vancomycin induced AKI , 2016, Scientific Reports.

[27]  M. Rossi,et al.  miRNA-Mediated KHSRP Silencing Rewires Distinct Post-transcriptional Programs during TGF-β-Induced Epithelial-to-Mesenchymal Transition. , 2016, Cell reports.

[28]  William A. Rennie,et al.  STarMirDB: A database of microRNA binding sites , 2016, RNA biology.

[29]  J. McCubrey,et al.  Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation. , 2016, Current pharmaceutical design.

[30]  C. Finelli,et al.  An increased expression of PI‐PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes , 2015, Journal of leukocyte biology.

[31]  Jiasun Lu,et al.  Regulation of growth of human bladder cancer by miR-192 , 2015, Tumor Biology.

[32]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[33]  S. Paolini,et al.  Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients , 2012, Leukemia.

[34]  M. Gobbi,et al.  Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment , 2012, Leukemia.

[35]  L. Cocco,et al.  The physiology and pathology of inositide signaling in the nucleus , 2011, Journal of cellular physiology.

[36]  A. Martelli,et al.  Nuclear inositide signaling in myelodysplastic syndromes , 2010, Journal of cellular biochemistry.

[37]  M Cazzola,et al.  Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells , 2010, Leukemia.

[38]  M. Baccarani,et al.  Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS , 2009, Proceedings of the National Academy of Sciences.

[39]  Aimee L Jackson,et al.  Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. , 2008, Cancer research.

[40]  C. Burge,et al.  Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.

[41]  C. Finelli,et al.  Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome. , 2006, International journal of molecular medicine.

[42]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[43]  Li Wang,et al.  Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. , 2006, Blood.

[44]  Stijn van Dongen,et al.  miRBase: microRNA sequences, targets and gene nomenclature , 2005, Nucleic Acids Res..

[45]  A. Martelli,et al.  Nuclear inositol lipid metabolism: More than just second messenger generation? , 2005, Journal of cellular biochemistry.

[46]  A. Martelli,et al.  Nuclear phospholipase C signaling through type 1 IGF receptor and its involvement in cell growth and differentiation. , 2005, Anticancer research.

[47]  A. Martelli,et al.  Metabolism and signaling activities of nuclear lipids , 2004, Cellular and Molecular Life Sciences CMLS.

[48]  A. Martelli,et al.  Up‐regulation of nuclear PLCβ1 in myogenic differentiation , 2003 .

[49]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[50]  C. Vasselon,et al.  Expression and prognostic significance of Bcl‐2 family proteins in myelodysplastic syndromes , 2002, American journal of hematology.

[51]  G. Mufti,et al.  The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. , 2000, Blood.

[52]  R. Davis,et al.  Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. , 1998, Leukemia research.

[53]  Y. Zhang,et al.  MicroRNA-124 inhibits colorectal cancer cell proliferation and suppresses tumor growth by interacting with PLCB1 and regulating Wnt/β-catenin signaling pathway. , 2019, European review for medical and pharmacological sciences.

[54]  Yue Zhai,et al.  miR-423-5p inhibits the proliferation and metastasis of glioblastoma cells by targeting phospholipase C beta 1. , 2019, International journal of clinical and experimental pathology.

[55]  Xiaohua Li,et al.  Low miR-192 expression predicts poor prognosis in pediatric acute myeloid leukemia. , 2018, Cancer biomarkers : section A of Disease markers.

[56]  Y. Suh,et al.  Phospholipase D1 Acts through Akt/TopBP1 and RB1 to Regulate the E2F1-Dependent Apoptotic Program in Cancer Cells. , 2017, Cancer research.

[57]  J. McCubrey,et al.  PLC-β1 and cell differentiation: An insight into myogenesis and osteogenesis. , 2017, Advances in biological regulation.

[58]  A. Martelli,et al.  Nuclear phospholipase C beta1 and cellular differentiation. , 2008, Frontiers in bioscience : a journal and virtual library.

[59]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[60]  A. Martelli,et al.  Up-regulation of nuclear PLCbeta1 in myogenic differentiation. , 2003, Journal of cellular physiology.